2 not yet recruiting, 2 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Da, Yuwei, M.D.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efgartigimod for Consolidation Therapy in gMG Myasthenia Gravis | Not yet recruiting | Da, Yuwei, M.D. | 130 | 2025-07-30 | 2025-07-22 | |
| Blinatumomab for Treatment of Refractory Myasthenia Gravis Blinatumomab - Myasthenia Gravis | Phase 2 / Phase 3 | Not yet recruiting | Da, Yuwei, M.D. | 2 | 2025-04-01 | 2025-03-25 |
| Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis Pyridostigmine, Prednisone, Tacrolimus, Pyridostigmine, Tacrolimus - Myasthenia Gravis | Unknown | Da, Yuwei, M.D. | 160 | 2021-01-01 | 2021-02-24 | |
| Clinical Prognosis and Progression of Myasthenia Gravis Patients Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) - Myasthenia Gravis | Unknown | Da, Yuwei, M.D. | 2000 | 2017-02-08 | 2021-08-23 |
Prednisone (2) · Pyridostigmine Bromide (2) · Tacrolimus (2) · Azathioprine (1) · Cyclophosphamide (1) · Cyclosporine (1) · Immunoglobulins, Intravenous (1) · Immunosuppressive Agents (1) · Methotrexate (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Steroids (1) · blinatumomab (1)
China (2)
Yuwei Da, M.D. (1)